NASDAQ · LXRX
Healthcare · Biotechnology
$1.65
Down-$0.03 (-1.79%)
Updated Oct 13, 2026, 5:58 AM
SID Score
3.9/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · LXRX
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 12, 2026
LXRX closed at $1.65 after 21 trading sessions, down 16.67% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 12, 2026 | $1.65 | $1.67 | $1.605 | $1.65 | 2.03M |
| Oct 9, 2026 | $1.75 | $1.77 | $1.67 | $1.68 | 2.07M |
| Oct 8, 2026 | $1.75 | $1.78 | $1.695 | $1.76 | 3.32M |
| Oct 7, 2026 | $1.73 | $1.77 | $1.7137 | $1.76 | 1.1M |
| Oct 6, 2026 | $1.75 | $1.78 | $1.72 | $1.75 | 1.64M |
| Oct 5, 2026 | $1.83 | $1.83 | $1.72 | $1.74 | 2.72M |
| Oct 2, 2026 | $1.85 | $1.87 | $1.80 | $1.82 | 2.32M |
| Oct 1, 2026 | $1.86 | $1.87 | $1.81 | $1.82 | 2.27M |
| Sep 30, 2026 | $1.89 | $1.95 | $1.8435 | $1.875 | 1.74M |
| Sep 29, 2026 | $1.92 | $1.94 | $1.80 | $1.88 | 3.95M |
| Sep 28, 2026 | $1.88 | $2.05 | $1.81 | $1.90 | 10.89M |
| Sep 25, 2026 | $1.87 | $1.93 | $1.765 | $1.795 | 3.05M |
| Sep 24, 2026 | $2.05 | $2.06 | $1.85 | $1.86 | 4.44M |
| Sep 23, 2026 | $2.17 | $2.17 | $2.02 | $2.06 | 3.17M |
| Sep 22, 2026 | $2.05 | $2.195 | $2.022 | $2.18 | 4.84M |
| Sep 21, 2026 | $2.05 | $2.0775 | $2.00 | $2.04 | 2.51M |
| Sep 18, 2026 | $2.04 | $2.06 | $1.99 | $2.05 | 7.46M |
| Sep 17, 2026 | $2.05 | $2.11 | $2.015 | $2.035 | 2.24M |
| Sep 16, 2026 | $2.01 | $2.055 | $2.00 | $2.02 | 2.15M |
| Sep 15, 2026 | $1.98 | $2.02 | $1.885 | $2.01 | 2.51M |
| Sep 14, 2026 | $1.97 | $2.01 | $1.935 | $1.98 | 1.77M |
The latest Smart Investors Daily articles mentioning LXRX.
Company
Market Activity
Research & News
LXRX research
Company profile and research snapshot.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, also developing LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 28, 2026 | Cantor Fitzgerald | Overweight | — |
| May 11, 2026 | Citigroup | Buy | — |
| Mar 23, 2026 | HC Wainwright & Co. | Buy | — |
| Mar 10, 2026 | Citigroup | Buy | — |
| Mar 5, 2026 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
Benzinga · Oct 6, 2026
Lexicon Pharmaceuticals (NASDAQ:LXRX) held its second-quarter earnings conference call on Thursday. Below is the complete transcript from the call. This transcript is brought to you by Benzinga APIs. For real-time
Yahoo · Oct 2, 2026
The analyst fair value estimate for Lexicon Pharmaceuticals has shifted from US$3.77 to US$4.55 per share, reflecting a higher modeled upside in the latest work. Recent Street commentary links this move to growing focus on sotagliflozin and the fully enrolled Phase 3 SONATA HCM trial, which has a defined data readout in 1Q27. As you read on, you will see how these factors shape the evolving Lexicon Pharmaceuticals story and what to watch as the narrative develops. Stay updated as the Fair...
Yahoo · Sep 28, 2026
An analyst at a prominent research firm initiated coverage of the
Yahoo · Sep 28, 2026
Investing.com -- Shares of Lexicon Pharmaceuticals Inc (NASDAQ:LXRX) rallied over 13% in Monday morning trading following a bullish initiation of coverage from Wall Street research firm Cantor Fitzgerald. The broker set an Overweight rating and an $8.00 price target on the biopharmaceutical company, reflecting substantial upside potential driven by the company’s ongoing late-stage cardiovascular research program.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning LXRX.
